Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum

被引：22
作者：
不详
机构：
[1] Department of Neurosurgery, Frenchay Hospital
[2] Clinical Sciences at North Bristol, University of Bristol
[3] Department of Neurology and Gene Therapy Center, University of Massachusetts, Worcester
来源：
HUMAN GENE THERAPY | 2011年 / 22卷 / 02期
基金：
英国医学研究理事会;
关键词：
D O I：
10.1089/hum.2010.129
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Convection-enhanced delivery (CED) of recombinant adeno-associated virus (rAAV) vectors is a promising approach for delivery of therapeutic transgenes to the brain. In this study we have systematically examined vector dosing in vivo. Infusions of rAAV serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10 expressing an enhanced green fluorescent protein reporter gene were undertaken into the striatum of rats and pigs using CED. Vector distribution, as defined by the volume of distribution and number of transduced cells following each infusion, was determined using stereological methods. Immunohistochemistry was used to determine the transductional tropism of serotypes and to evaluate for the presence of immune cell infiltration into the brain. Vector distribution was highly variable between serotypes. Infusion rate had no significant effect on vector distribution or the occurrence of tissue damage. For serotypes 2/1, 2/2 and 2/rh10, as the vector concentration was increased beyond 10(12) vg/ml, no increase in vector distribution was observed. In contrast, for serotypes 2/rh8 and 2/9, retrograde axonal transport was observed above this threshold concentration. Cell transduction was principally neuronal for all serotypes and was associated with a low-level immune response. In planning clinical trials it is critical that these observations are considered in order to achieve optimal vector dosing.
引用
收藏
页码：237 / 251
页数：15
相关论文
共 45 条
  • [1] Hunt Bobo R., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H., Convection-enhanced delivery of macromolecules in the brain, Proceedings of the National Academy of Sciences of the United States of America, 91, 6, pp. 2076-2080, (1994)
  • [2] Bonneville F., Welter M.L., Elie C., Tezenas Du Montcel S., Hasboun D., Menuel C., Houeto J.L., Bonnet A.M., Mesnage V., Pidoux B., Navarro S., Cornu P., Agid Y., Dormont D., Parkinson disease, brain volumes, and subthalamic nucleus stimulation, Neurology, 64, 9, pp. 1598-1604, (2005)
  • [3] Broekman M.L.D., Comer L.A., Hyman B.T., Sena-Esteves M., Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain, Neuroscience, 138, 2, pp. 501-510, (2006)
  • [4] Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., Muzyczka N., Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system, Molecular Therapy, 10, 2, pp. 302-317, (2004)
  • [5] Cearley C.N., Wolfe J.H., Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain, Molecular Therapy, 13, 3, pp. 528-537, (2006)
  • [6] Chen M.Y., Hoffer A., Morrison P.F., Hamilton J.F., Hughes J., Schlageter K.S., Lee J., Kelly B.R., Oldfield E.H., Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system, Journal of Neurosurgery, 103, 2, pp. 311-319, (2005)
  • [7] Chen M.Y., Lonser R.R., Morrison P.F., Governale L.S., Oldfield E.H., Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time, Journal of Neurosurgery, 90, 2, pp. 315-320, (1999)
  • [8] Chirmule N., Propert K.J., Magosin S.A., Qian Y., Qian R., Wilson J.M., Immune responses to adenovirus and adeno-associated virus in humans, Gene Therapy, 6, 9, pp. 1574-1583, (1999)
  • [9] Cunningham J., Oiwa Y., Nagy D., Podsakoff G., Colosi P., Bankiewicz K.S., Distribution of AAV-TK following intracranial convection-enhanced delivery into rats, Cell Transplantation, 9, 5, pp. 585-594, (2000)
  • [10] Cunningham J., Pivirotto P., Bringas J., Suzuki B., Vijay S., Sanftner L., Kitamura M., Chan C., Bankiewicz K.S., Biodistribution of adeno-associated vrus type-2 in nonhuman primates after convection-enhanced delivery to brain, Molecular Therapy, 16, 7, pp. 1267-1275, (2008)
12345